Physician profile
Charles E Kelly
NPI 1780678979
$1,778.30
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $91.06 · 2021: $147 · 2022: $224 · 2023: $407 · 2024: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.53 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.35 | 2019-2024 | Trulance |
| Teva Pharmaceuticals USA, INC. | $232.94 | 2023-2024 | Austedo Xr, Ajovy, Austedo |
| Gilead Sciences, INC. | $192.85 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $141.46 | 2024 | Voquezna |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Pfizer INC. | $97.95 | 2022 | |
| Nestle Healthcare Nutrition INC. | $58.25 | 2021-2023 | |
| Ucb, INC. | $32.81 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $30.02 | 2022-2023 | Cimzia |
| Intercept Pharmaceuticals, INC. | $30.00 | 2023 | Ocaliva |
| Ardelyx, INC. | $23.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.69 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.11 | 2020 | |
| Daiichi Sankyo INC. | $16.45 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $12.85 | 2023 | Linzess |
| Allergan, INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.